Treating postpartum depression on the way

A recently approved pill in the U.S. will soon be available in Mexico and other countries

According to research in the field of psychosocial, one in eight postpartum women suffers from postpartum depression.

Postpartum depression (PPD) is a disorder that occurs in women after childbirth and can be detected immediately by symptoms such as mood swings, crying, anxiety and trouble sleeping.

According to research in the field of psychosocial, one in eight postpartum women suffers from postpartum depression.

Dr. Manuel Alfonso Gonzalez Oscoi, a scholar at the Department of Psychology at the National Autonomous University of Mexico, explained that postpartum depression may precede depression during pregnancy due to hormonal changes, psychosocial factors , acceptance or rejection of pregnancy, etc.

Mood changes in the first three days postpartum were classified as “normal.”

However, there are also warning signs that may be a sign of postpartum depression, such as eating disorders, lethargy, anxiety, mood swings from one extreme to another, i.e. happy to sad in a short period of time, and sometimes rejection and depression. Feeling guilty about the baby.

According to the case study, depression can start in pregnancy and continue for several months after the baby is born. Until a few days ago, one of the treatments for this disorder was psychotherapy combined with intravenous antidepressants, which had positive effects in women. Now, a new drug for postpartum depression can work in just three days.

The Food and Drug Administration (FDA) has approved the first drug in the United States to treat postpartum depression. This is the drug Zurzuvae (Zuranolone), the first oral drug to treat this disease.

According to a statement, “In Study 1, patients received Zurzuvae 50 mg or placebo once daily in the evening for 14 days. In Study 2, patients received another zuranolone product at a dose approximately equivalent to Zurzuvae 40 mg or placebo, also for 14 days.”

To evaluate the trials, patients in both studies were monitored for at least 4 weeks after 14 days of treatment. The results were as follows: Compared with the placebo group, patients in the Zurzuvae group experienced a significant improvement in symptoms. On day 42, 4 weeks after the last dose of Zurzuvae, the therapeutic effect was maintained.

Dr. Víctor Marín, an obstetrician specializing in high-risk pregnancy, colposcopy, and reproduction, spoke with the following team Keep improving It also emphasizes the importance of appropriate treatment to treat PPD.

He noted that it is important to consider psychotherapy as an adjunct to any drug treatment to improve the balance of brain changes caused by the condition.

Medication without psychotherapy, without management or trying to address a woman’s psychological and emotional issues is not going to work, and medication alone will not achieve the results we want,” he said.

Based on clinical studies, taking Zurzuvae may affect a person’s ability to drive and perform other potentially dangerous activities, so women taking the drug are advised to avoid driving or operating heavy machinery for at least 12 hours after taking the drug. .

Common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. Other issues the FDA warns about and the appearance of suicidal thoughts and behaviors that may alert consumers.

Although the drug is approved, it is not yet on the market. The drug is expected to be available in the U.S. later this year, and to start selling to Mexico and other countries within a few years.

Source link

Leave a Comment